Axsome Therapeutics (NASDAQ: AXSM) shares preliminary 2025 net revenue

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. filed a Form 8-K to report that it issued a press release titled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.” The company is furnishing the press release as Exhibit 99.1 under Item 2.02, covering results of operations and financial condition, and also referencing it under Item 8.01 as an other event.

The company specifies that the information in Item 2.02, including Exhibit 99.1, is being furnished rather than filed, so it is not subject to liability under Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings unless specifically stated. The exhibit list confirms the press release and the related cover page data file as the primary attachments.

Insights

Equity research analyst

Axsome furnishes preliminary 2025 net product revenue data via press release.

Axsome Therapeutics is using this Form 8-K to point investors to a press release with preliminary figures for its fourth quarter and full year 2025 net product revenue. This indicates an intention to give the market an early view of top-line commercial performance before full financial statements are available, but the specific revenue amounts and any comparisons are contained in the attached press release, not in this summary.

The company classifies the disclosure under Item 2.02 for results of operations and also under Item 8.01 as an other event, while clearly stating that the information is “furnished” rather than “filed.” That means the preliminary revenue details in Exhibit 99.1 are not automatically subject to Section 18 liability or incorporated into other filings unless explicitly referenced, a common approach for preliminary metrics.

From an investment perspective, the importance of this event depends entirely on the revenue levels and trends described in Exhibit 99.1, which are not repeated here. Subsequent periodic reports containing full financial statements will provide more comprehensive context around profitability, expenses, and cash flows alongside these preliminary net product revenue figures.

0001579428false00015794282026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Axsome Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37635	45-4241907
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
One World Trade Center, 29th Floor
New York, New York				10007
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (212) 332-3241

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per Share		AXSM		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release entitled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.”

For purposes of this Item 2.02, the Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

As reported above, on January 12, 2026, the Company issued a press release entitled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.” For purposes of this Item 8.01, the full text of the press release is also being filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated January 12, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Axsome Therapeutics, Inc.
Date:	January 12, 2026	By:	/s/ Herriot Tabuteau, M.D.
		Name: Title:	Herriot Tabuteau, M.D. President and Chief Executive Officer

FAQ

What did Axsome Therapeutics (AXSM) disclose in this Form 8-K?

Axsome Therapeutics reported that it issued a press release titled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue,” and it furnished that press release as Exhibit 99.1.

Which financial information does Axsome Therapeutics (AXSM) highlight in the related press release?

The related press release provides preliminary net product revenue for Axsome Therapeutics’ fourth quarter and full year 2025.

How is the Axsome Therapeutics (AXSM) press release treated for SEC purposes?

The press release included in Item 2.02, along with Exhibit 99.1, is being furnished rather than filed, so it is not subject to Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Under which items does Axsome Therapeutics (AXSM) report this event?

Axsome Therapeutics reports the press release under Item 2.02, Results of Operations and Financial Condition, and Item 8.01, Other Events.

What exhibits are attached to this Axsome Therapeutics (AXSM) Form 8-K?

The Form 8-K lists Exhibit 99.1, the press release dated January 12, 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Axsome Therapeutics (AXSM) Form 8-K?

The Form 8-K was signed on behalf of Axsome Therapeutics, Inc. by Herriot Tabuteau, M.D., its President and Chief Executive Officer.